Traitement des tumeurs neuro-endocrines par les peptides radiomarqués

Translated title of the contribution: Peptide receptor radionuclide therapy of neuroendocrine tumours

L. Bodei, F. Giammarile

Research output: Contribution to journalArticlepeer-review


Neuroendocrine tumours are considered relatively rare tumours that have the characteristic property of secreting bioactive substances, such as amines and hormones. They constitute a heterogeneous group, characterized by good prognosis, but important disparities of the evolutionary potential. In the aggressive forms, the therapeutic strategies are limited. The metabolic or internal radiotherapy, using radiolabelled peptides, which can act at the same time on the primary tumour and its metastases, constitutes a tempting therapeutic alternative, currently in evolution. The prospects are related to the development of new radiopharmaceuticals, with the use of other peptide analogues whose applications will overflow the framework of the neuro-endocrine tumours.

Translated title of the contributionPeptide receptor radionuclide therapy of neuroendocrine tumours
Original languageFrench
Pages (from-to)142-147
Number of pages6
JournalMedecine Nucleaire
Issue number3
Publication statusPublished - Mar 2009


  • Neuroendocrine tumours
  • Radiolabelled peptide
  • Therapy

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology


Dive into the research topics of 'Peptide receptor radionuclide therapy of neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this